<DOC>
	<DOCNO>NCT00358410</DOCNO>
	<brief_summary>This study design examine idea GW679769 effect three pathophysiological disturbance report patient Functional Dyspepsia ( FD ) : impaired stomach accommodation meal , delay stomach empty , visceral hypersensitivity distension .</brief_summary>
	<brief_title>An Exploratory Study Examining The Effects Of Taking GW679769 Once-Daily For 4 Days In Patients With Functional Dyspepsia</brief_title>
	<detailed_description>An exploratory study investigate effect NK1 antagonist GW679769 , 120 mg daily 4 day , gastric accommodation , gastric empty gastric distension-induced perception discomfort adult male female patient functional dyspepsia , single-centre , placebo-controlled , double-blind , randomised , two-period crossover study</detailed_description>
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Casopitant</mesh_term>
	<criteria>Inclusion criterion : Functional dyspepsia diagnose accord Rome II criterion Must one month trial ( full dose ) proton pump inhibitor treatment within last 6 month , symptomatic period , produce lasting response , although may require patient symptoms heartburn present painpredominant dyspepsia symptom . Such decision leave Principal Investigator 's discretion . Patients nonsmoker smoker smoke 20 cigarette per day Exclusion criterion : Active history peptic ulcer disorder History major abdominal surgery History underlie psychiatric illness , current active psychiatric morbidity Pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Functional Dyspepsia</keyword>
	<keyword>Barostat</keyword>
	<keyword>Stomach</keyword>
</DOC>